Variable | Progression | Minimal clinical important difference (MCID ≥5) | ||||
---|---|---|---|---|---|---|
B | 95% CI | p | OR | 95% CI | p | |
Strategy (monotherapy) | 1.79 | 0.75–2.82 | 0.001 | 2.66 | 1.21–5.82 | 0.015 |
TJC28 | −0.11 | −0.20– -0.01 | 0.033 | 0.89 | 0.81–0.98 | 0.016 |
SJC28 | 0.01 | −0.10–0.13 | 0.805 | 1.03 | 0.96–1.10 | 0.471 |
ESR | 0.03 | 0.00–0.05 | 0.033 | 1.02 | 1.00–1.03 | 0.038 |
CRP | 0.02 | −0.00–0.04 | 0.084 | 1.01 | 1.00–1.02 | 0.071 |
Wellbeing | −0.01 | −0.04–0.01 | 0.196 | 0.99 | 0.98–1.01 | 0.319 |
PCS | 0.01 | −0.07–0.09 | 0.803 | 1.02 | 0.97–1.07 | 0.467 |
MCS | −0.03 | −0.09–0.04 | 0.408 | 1.01 | 0.97–1 .05 | 0.653 |
RF | 0.09 | −0.45–0.62 | 0.755 | 0.78 | 0.54–1.14 | 0.202 |
Anti-CCP positive | 0.86 | −0.23–1.95 | 0.123 | 2.41 | 1.04–5.57 | 0.040 |
Age | 0.04 | 0.00–0.08 | 0.042 | 1.02 | 0.99–1.05 | 0.251 |
Gender | 0.28 | −0.82–1.38 | 0.621 | 0.75 | 0.36–1.56 | 0.443 |
DAS28_ESR | −0.02 | −0.51–0.47 | 0.948 | 0.94 | 0.67–1.31 | 0.708 |
Remission 52 weeks | −0.83 | −2.07–0.41 | 0.188 | 0.64 | 0.29–1.42 | 0.272 |
Remission 6 months | −0.73 | −1.79–0.34 | 0.179 | 0.54 | 0.26–1.11 | 0.094 |
Remission 3 months | −0.90 | −1.99–0.19 | 0.104 | 0.71 | 0.33–1.54 | 0.388 |
HAQ-SDI | 0.62 | −0.46–1.69 | 0.260 | 1.00 | 0.54–1.85 | 0.994 |
BMI | −0.05 | −0.17–0.07 | 0.417 | 0.91 | 0.83–1.00 | 0.039 |
Injection triamcinolone | −1.63 | −2.81– -0.46 | 0.007 | 0.39 | 0.15–1.07 | 0.067 |